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SYMPOSIUM ON COMMERCIAL 
SPEECH AND PUBLIC HEALTH 
Jonathan H Adlert 
INTRODUCTION 
Americans have access to more health-related information today 
than ever before. Consumers are bombarded with medical messages 
and flooded with health-based claims. Television and magazine adver-
tisements inform consumers about everything from insomnia and 
erectile dysfunction to the importance of dietary fiber and the alleged-
ly wondrous properties of pomegranates. Product labels and promo-
tions provide more food for thought about fat, sodium, and carbohy-
drates; nutritional supplement makers further supplement consumer 
nutritional information. Were that not enough, the internet provides 
access to still more data (and opinion), much of it of questionable 
provenance and reliability. 
Does this cornucopia of information inform consumers and make 
them better off? Or is it too much? Can consumers adequately process 
all the messages they receive to make more informed decisions? If 
health information overload is producing a cacophony of competing 
voices, do consumers need help from government agencies or other 
expert intermediaries? And is the problem one of quantity or quality? 
That is, would consumers be better off bearing less, or just hea.r!ng 
less information of a certain type from certain sources. More informa-
tion may be better only if it is sufficiently accessible, educational; and 
reliable. 
The policy calculus is complicated by the constitutional protection 
of commercial speech. For several decades, the Supreme Court bas 
held that the First Amendment protects commercial speech, including 
advertisements and product promotions. As the Court explained in 
United States v. United Foods, "[t]he fact that the speech is in aid of a 
COillluercial pu1 pose does not deprive respondent of all First Amend-
ment protection." 1 Protections provided for commercial speech may 
t Professor of Law and Director of the Center for Business Law & Regula-
tion, Case Western Reserve University School ofLaw. 
1 533 U.S. 405, 410 (2001). 
1 
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be less robust than those for core political speech (at least for now), 
but are still substantial. 2 Among other things, the Comi bas held the 
First Amendment embodies a clear preference for more speech, not 
less. This doct1ine applies with no less force in the health context. 
From the start, the Supreme Court has applied its commercial free 
speech doctrines in a health-policy context, begill11mg with Virginia 
State Board of Pharmacy v. Virginia Citizens Consumer CozmciP in 
1976 and continuing through Thompson v. Western States Medical 
Center. 4 
Does the constitutional protection of commercial speech impair 
the govermnent's ability to protect and promote public health? Or 
does the commercial speech doctline itself enhance consumer educa-
tion and harness market competition to advance public health? Do 
First Amendment limitations on regulation of commercial messages 
unduly retard govetnmental efforts to safeguard consumers? Or do 
they properly constrain illiberal paternalism? If the Court has been 
over-protective of health-related commercial speech, is there a ptin-
cipled place to redraw the line? And how should those gove1nmental 
agencies entrusted with the power to protect public health and welfare 
respond to these constitutional constraints? 
The editors of Health _Matrix have assembled a group of experts 
fi"om academia and legal practice to address these and related ques-
tions arising at the intersection of commercial speech and public 
health. Some contributors focus on the legal and constitutional ques-
tions provoked by First An1endment protection of health-related 
commercial speech, while others focus on matters of policy. The re-
sulting collection seeks to inform the ongoing debate about the best 
legal and prudential balance between commercial free speech and 
public health, particularly in the context of Food and Drug Adminis-
2 The current test for the constitutionality of limitations on commercial 
speech is provided by Central Hudson Gas & Electric Corp. v. Public Service Com-
mission, 447 U.S. 557, 566 (1980). Under this test, if speech concems lawf11l activity 
and is not misleading, the govcmment can adopt regulations pursuant to a "substan-
tiai" govemmentai interest, but only if the regulations ~"directly advance" and are not 
more extensive than necessary to advance the stated interest. 
While the Court continues to apply the Central Hudson test, several justic-
es on the Court have signaled their disagreement with it. See 44 Liquormart, Inc. v. 
Rhode Island, 517 U.S. 484 (1996); see also United Foods, 533 U.S. at409-10 (not-
ing "criticism" of Central Hudson test by multiple justices); Thompson v. W. States 
Med. Ctr., 535 U.S. 357, 367-68 (2002) (same). 
3 425 U.S. 748 (1976) (holding that a slate ban on advertising prescription 
drug prices by licensed pharmacists violates the First Amendment). 
·I 535 U.S. 357 (2002) (holding that a federal prohibition on advertising 
preparation of compounded drugs violates the First Amendment). 
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tration (FDA) regulation of pharmaceuticals and other medical tech-
nologies. 
Economist J. Howard Beales, former Director of the Federal 
Trade Con:nnission's Bureau of Consumer Protection, surveys the 
economic literature on the market for information and considers its 
impact on commercial speech in the public health context. 5 His Ar-
ticle warns of the often-overlooked costs of limiting a robust market-
place of product-related and health-related information and questions 
the presumption that governmental restrictions on health-related in-
formation will advance public health. According to Beales, govern-
ment intervention in the market for health-related information should 
focus on enhancing market performance, such as by reducing informa-
tion costs and protecting against false or m.:isleading claims, rather 
than directing or supplanting market outcomes. Ensuring the reliabili-
ty and availability of relevant information is almost always preferable 
to suppressing information, he argues, noting that regulation of com-
mercial speech may have unintended and potentially counterproduc-
tive effects. Thus, his paper questions whether the ubiquity of health-
related commercial speech is much of a problem at all. 
Professor Lars Noah argues that there exists a conflict between 
the Supreme Court's "robust" commercial speech doctrine and the 
FDA's efforts to protect public health through the regulation of phar-
maceuticals and other medical technologies. 6 According to Noah, 
efforts to restrict or suppress information about drugs and devices are 
in tension with underlying First Amendment values and face greater 
judicial opposition than more targeted efforts to prevent fraud, cure 
potentially misleading messages, or otherwise promote health-related 
messages. Noah suggests that there is an inherent problem with apply-
ing a legal framework developed around the regulation of "vice prod-
ucts" to the regulation of drugs and other medical technologies, and 
that the FDA needs to confront the limitations existing commercial 
speech doctrine imposes on regulatory efforts. 
Professor emeritus Margaret Gilhooley focuses on direct-to-
consumer drug advertisements. 7 Summarizing arguments she has 
made at greater length elsewhere, 8 she argues that the First Amend-
5 See J. Howard Beales III, Health Related Claims, the Market for Infonna-
tion, and the First Amendment, 21 HEALTH MATRIX 7 (20 11 ). 
6 See Lars Noah, Tmth or Consequences?: Commercial Free Speech vs. 
Public Health Promotion (atthe FDA), 21 HEALTH MATRIX 31 (2011). 
7 See Margaret Gilhooley, Commercial Speech, Drugs, Promotion and a 
Tailored Advertisement Moratorium, 21 HEALTH MATRIX 97 (2011). 
8 See Margaret Gilhooley, Dmg Safety and Commercial Speech: Television 
Advertisements and Reprints on Off-Label Uses, 47 SAN DIEGO L. REv. 845 (201 0). 
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ment does not preclude Congress from regulating direct-to-consumer 
commercial messages about drugs, particularly with regard to off-
label uses. If adoption of such a policy requires the Supreme Court to 
revisit Western States, she would welcome this development if it were 
to allow the FDA to adopt further protections for public health. 
Former FDA Chief Counsel Gerald Masoudi and Christopher 
Pruitt encourage a more cautious approach to the regulation of com-
mercial speech in the health context. 9 According to Masoudi and 
Pruitt, several existing FDA policies and regulations already curtail 
constitutionally protected commercial speech. Allowing a government 
agency to serve as a "gatekeeper of speech" is troubling, they argue, 
particularly since some regulatory policies can be difficult to chal-
lenge in court. As a consequence, Masoudi and Pruitt urge the FDA to 
continue the initiative it began in 2002 to review whether its regula-
tions, policies, and enforcement practices are consistent with First 
Amendment values. 10 
Gregory Conko takes an equally skeptical view of FDA regulation 
of speech, focusing on FDA policies regarding "off-label" uses of 
pharmaceuticals and medical devices. 11 While the FDA is concerned 
about the promotion of unapproved uses for regulated drugs and de-
vices, Conko argues such risks may be outweighed by the potential 
benefits of such uses, and that drug companies and device manufac-
turers should not be barred from promoting off-label uses. Conko ar-
gues that the FDA's current policy is unwise and likely unconstitu-
tional, and suggests alternative, less-burdensome ways the agency 
could address concerns about health risks from unapproved uses. 
Professor David Y osifon takes an entirely different tack, side-
stepping the First Amendment questions altogether and focusing in-
stead on the corporate form and the obligations of corporate manag-
ers. 
12 Professor Y osifon believes corporations have a tendency to 
communicate with consumers in ways that advance corporate interests 
at the expense of public health. Yet his Article suggests the problem is 
not First Amendment protection of corporate or commercial speech, 
but the internal norms that allow corporate executives to disseminate 
misleading or unhelpful messages to their customers. Y osifon sug-
9 See Gerald Masoudi & Christopher Pruitt, The Food & Drug Administra-
tion v. The First Amendment: A Survey of Recent FDA Enforcement, 21 HEALTH 
MATRIX 111 (2011). 
10 See 67 Fed. Reg. 34,942 (May 16, 2002). 
11 See Gregory Conko, Hidden Truth: The Perils and Protection of Off-Label 
Drug and Medical Device Promotion, 21 HEALTH MATR1X 149 (201 1). 
12 See David G. Yosifon, Discourse Nonns as Default Rules: Stmcturing 
Corporate Speech to Multiple Stakeholders, 21 HEALTH MATRIX 189 (201 1). 
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gests that reconceiving the obligations of corporate managers to en-
compass the well-being of consumers and other stakeholders could be 
a more effective way to constrain corporate behavior without trigger-
ing conflicts over the proper scope of commercial free speech. 
Information is power-the power to protect and persuade, and 
perchance to manipulate and mislead. The power to control informa-
tion entails great power over individual behavior and collective 
choice. The First Amendment, as currently understood, significantly 
limits the government's ability to restrain or control what information 
the public receives. If the government wants to influence or channel 
consumer choices, it may have to regulate conduct directly or seek to 
induce desired behavior by releasing yet more information into exist-
ing streams. The First Amendment makes it easier for government to 
increase the flow than control the current. 
As the torrent of health-related information accumulates, policy-
makers will confront still more questions about the desirability and 
efficaciousness of measures designed to enhance health and welfare. 
The First Amendment's limitations may be a good thing, or they may 
unduly constrain public-spirited interventions. Either way, questions 
about the proper balance between commercial speech and public 
health will remain with us for some time. 
